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TamoxifenThe present study aimed to investigate the effects of tamoxifen (TMX) on locomotor behavior and on the
activities of mitochondrial respiratory chain complexes and creatine kinase (CK) in the brain of rats subjected
to an animal model of mania induced by D-amphetamine (D-AMPH)—reversion and prevention protocols. The
D-AMPH administration increased locomotor activity in saline-treated rats under prevention and reversion
treatment; furthermore, there was evident reduction in the locomotion in the D-amphetamine group treated
with TMX. D-AMPH signiﬁcantly decreased the activity of mitochondrial respiratory chain complexes in
saline-treated rats in prefrontal cortex, hippocampus, striatum and amygdala in both prevention and
reversion treatment. Depending on the cerebral area and evaluated complex, TMX was able to prevent and
reverse this impairment. A decrease in CK activity was also veriﬁed in the brain of rats when D-AMPH was
administrated in both experiments; the administration of TMX reversed but not prevented the decrease in CK
activity induced by D-AMPH. The present study demonstrated that TMX reversed and prevented the
alterations in behavioral and energy metabolism induced by D-AMPH (alterations were also observed in
bipolar disorder), reinforcing the need for more studies about inhibitors of PKC as possible targets for new
medications in the treatment of bipolar disorder.s, PPGCS,UNASAU,Universidade
razil. Tel.: +55 48 3431 2578;
vier OA license.© 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Bipolar disorder (BD) is a common and severe mood disorder that
causes recurrent mood switches including manic, depressive, and
mixed episodes (Manning et al., 1997). This condition is associated to
emotionally damaging behaviour and bears a 15% risk of suicide when
left untreated (McIntyre et al., 2008).
The mania, considered the clinical hallmark of the disease, shows
symptoms such as euphoria, excessive energy, grandiosity, accelera-
tion, intense sensation of pleasure or a highly irritable and aggressive
state (Calabrese et al., 2003). The treatment of acute mania with
lithium, valproate, carbamazepine and atypical antipsychotics has
shown great progress, however many patients do not tolerate orrespond adequately to these drugs (Evins et al., 2006). In addition,
these treatments necessitate continuous long-term use and are thus
non-curative (Ludtmann et al., 2011), requiring new approaches in BD
pharmacotherapy.
Evidences from literature strongly suggest a dysregulation of
mitochondrial function and energetic metabolism in the pathophys-
iology of neuropsychiatric disorders, including BD (Kato and Kato,
2000; Konradi et al., 2004; Quiroz et al., 2008). In this context, in vivo
magnetic resonance spectroscopy studies have demonstrated changes
in brain compounds related to energy production, oxidative phos-
phorylation and phospholipid metabolism in bipolar patients (Stork
and Renshaw, 2005). Moreover, neuroimaging studies (Cecil et al.,
2002; Bertolino et al., 2003; Deicken et al., 2003), postmortem brain
(Konradi et al., 2004; Vawter et al., 2006), and animal models (Corrêa
et al., 2007; Valvassori et al., 2010) suggest that the decrease in
mitochondrial function with consequent impairment of cell energy
production is a hypothesis which might explain the pathophysiology
of BD. These observations suggest that enhancing mitochondrial
Scheme 1. Treatment regime in reversal protocol.
Scheme 2. Treatment regime in prevention protocol.
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term treatment of BD (Quiroz et al., 2008).
Creatine kinase (CK) is an enzyme that plays a central role in cells
with high and ﬂuctuating energy requirements, including neurons
(Andres et al., 2008), where it acts as an effective buffering system of
cellular ATP levels. A study by MacDonald et al. (2006) showed that
the expression levels of mRNA transcripts coding for brain creatine
kinase and mitochondrial 1 ubiquitous are downregulated in the
hippocampus and dorsolateral prefrontal cortex in the postmortem
brain of bipolar patients. Additionally, in an animal model of mania,
was demonstrated that the levels of CK are decreased in brain tissue
(Streck et al., 2008).
Several lines of evidence also implicate abnormal protein kinase
C (PKC) activity in BD. This protein is mainly found in the brain, where
it exerts fundamental role in pre and post-synaptic neurotransmis-
sion, regulating neuronal excitability, neurotransmitter release and
cellular plasticity (Manji and Lenox, 1999). Psychostimulant drugs
seem to activate PKC (Einat et al., 2007; Boudanova et al., 2008) and
evidences suggest that lithium and valproate attenuate the function of
this protein, indicating that PKC modulation plays a key role in the
treatment of mania (Chen et al., 2000; Kirshenboim et al., 2004; Hahn
et al., 2005). Recent preclinical and clinical studies have demonstrated
that tamoxifen (TMX—an inhibitor of PKC) signiﬁcantly reduces
hyperactivity and risky behavior caused by D-AMPH administration in
animals and also reduces manic symptoms in patients (Bebchuk et al.,
2000; Einat et al., 2007; Zarate et al., 2007; Yildiz et al., 2008), suggesting
efﬁcacy of TMX in the treatment of mania. In addition, Tuquet et al.
(2000) demonstrated that TMX interacts with mitochondrial respira-
tory chain in the isolated mitochondria from rat liver, suggesting a
correlation between PKC inhibition and increased energy metabolism.
The ﬂuctuating pattern of BD hampers the development of a suitable
animalmodel that includes all the symptomsof thedisorder. The clinical
hallmark for the diagnosis of BD is the presence of manic symptoms
(Belmaker, 2004) so the usual animal models for BD are focused on the
expression of a single manic episode. The psychostimulant-induced
hyperactivity is the best established animal model of mania (Machado-
Vieira et al., 2004). It causes hyperlocomotion, insomnia and increased
sexual drive, representing face validity (Fiorino and Phillips, 1999), it
reproduces pathophysiological characteristics of the human condition
(construct validity) (Frey et al., 2006d), and responses to antimanic
agents, such as antipsychotics andmood stabilizers (predictive validity)
(Frey et al., 2006b,c).
In this context, the present study aimed to investigate the effects of
tamoxifen on locomotor behavior, on the activity of mitochondrial
respiratory chain complexes and on CK activity in brains of rats
subjected to an animal model of mania induced by D-AMPH.
2. Materials and methods
2.1. Animals
AdultsmaleWistar rats (250–300 g)were obtained from the Central
Animal House of Universidade do Extremo Sul Catarinense. These
animals were maintained on a 12-h light–dark cycle (lights on at 7:00
am), at a temperature of 23 °C±1 °C and with free access to food and
water. These conditions were maintained constant throughout the
experiments. The rats were caged in groups of ﬁve in a 41×34×16 cm
cage anddivided randomly in 12 animals per group, totaling 96 animals.
All behavioral data were conducted in a calm room by an experienced
observer. The observer was in the room where experiments were
performed and was blind to the animal condition.
All experimental procedureswere carriedout in accordancewith the
National Institutes of Health Guide for the Care and Use of Laboratory
Animals and the Brazilian Society for Neuroscience and Behavior
(SBNeC) recommendations for animal care, with the approval of the
local Ethics Committee of Animals Use.2.2. Drugs
Tamoxifen citrate (Salutas Pharma GmbH, Barleben, Ger.) and
D-amphetamine (Sigma, St Louis,Mo.)were directly dissolved in saline
(Sal) solution (NaCl 0.9%, w/v) and used in doses based on previous
studies (TMX Einat et al., 2007; D-AMPH—Frey et al., 2006c).2.3. Reversal treatment
In the reversal model, we reproduced the treatment of acutemanic
episode according previously proposed (Frey et al., 2006c). Rats
received intraperitoneal (i.p.) injection of either D-AMPH (2 mg/kg)
or Sal (1 mL/kg) once a day for a period of 14 days. From the 8th to the
14th day (treatment for 7 days), D-AMPH and Sal treated animals also
received Sal (1 mL/kg i.p.—twice a day) or TMX (1 mg/kg i.p.—twice
a day), totaling four experimental groups of 12 animals per group:
Sal+Sal, Sal+TMX, D-AMPH+Sal and D-AMPH+TMX. No behavioral
assessment was performed between days 1–14. On the 15th day of
treatment, the animals received a single injection of D-AMPH or Sal and
locomotor activity was assessed using the open-ﬁeld test 2 h after
the injection, sincepharmacokinetics studies have shown that half life of
D-AMPH in the body is 60 min (Honecker and Coper, 1975). The rats
were killed by decapitation immediately after the open-ﬁeld test and
prefrontal cortex, hippocampus, striatum and amygdala were manually
dissected on ice, rapidly frozen on dry ice and stored at −70 °C until
assayed (See Scheme 1).2.4. Prevention treatment
This protocol was designed to mimic the prevention phase of BD
treatment, as previously proposed (Frey et al., 2006c). Rats received
either Sal (1 mL/kg i.p.—twice a day) or TMX (1 mg/kg i.p.—twice a day)
for a period of 14 days. From the 8th to the 14th day (treatment for
7 days), TMX and Sal treated animals also received Sal (1 mL/kg i.p.—
once a day) or D-AMPH (2 mg/kg—once a day), totaling four
experimental groups of 12 animals per group: Sal+Sal, TMX+Sal,
Sal+D-AMPH and TMX+D-AMPH. No behavioral assessment was
performed between days 1 and 14. On the 15th day of treatment, the
animals received a single injection of D-AMPH or Sal and locomotor
activitywasassessedusing theopen-ﬁeld test 2 h after the injection. The
rats were killed by decapitation immediately after the open-ﬁeld test
and prefrontal cortex, hippocampus, striatum and amygdala were
manuallydissectedon ice, rapidly frozenondry iceand stored at−70 °C
until assayed (See Scheme 2).
Fig. 1. Numbers of crossings and rearings in reversal model. (n=12 for each group).
Data were analyzed by two-way analysis of variances followed by Tukey test when p
was signiﬁcant. Values are expressed as mean±S.E.M. * pb0.05 difference of Sal+Sal
group. # pb0.05 difference of D-AMPH+Sal group. Bars represent means; error bars
represent standard error of means.
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On the 15th day of treatment, the animals received a single
injection of D-AMPH or Sal, and 2 h after the injection locomotor
activity was measured using the open-ﬁeld test. The test was
performed in a 40×60 cm open ﬁeld surrounded by 50 cm high
walls. The ﬂoor of the apparatus was constructed with varnished
wood and divided into 9 equal rectangles by black lines. The animals
were gently placed in one of the corner squares at the start of the test
in order to explore the arena for 5 min. Crossings of the black lines and
rearings (exploratory activity) were counted.
2.6. Activity of mitochondrial respiratory chain enzymes
Prefrontal cortex, hippocampus, striatum and amygdala were
homogenized (1:10, w/v) in SETH buffer (250 mM sucrose, 2 mM
EDTA, 10 mMTrizma base, 50 IU/ml heparin, pH 7.4). The homogenates
were centrifuged at800 g for 10 min and the supernatantswere used for
determining the activities of the mitochondrial respiratory chain
enzymes (complexes I, II, III and IV). On the day of the assays, the
sampleswere frozen and thawed thrice inhypotonic assaybuffer to fully
expose the enzymes to substrates and achievemaximal activities. NADH
dehydrogenase (complex I) was evaluated by the method described by
Cassina and Radi (1996) by the rate of NADH-dependent ferricyanide
reduction at l=420 nm. The activities of succinate-2,6-dichloroindo-
phenol (DCIP)-oxidoreductase (complex II) and succinate: Cytochrome
c oxidoreductase (complexes II–III) were determined by the method
described by Fischer et al. (1985). Complex II activity was measured by
following the decrease in absorbance due to the reduction of 2,6-DCIP
at l=600 nm. Complex II–III activity was measured by cytochrome c
reduction from succinate at l=550 nm. The activity of cytochrome c
oxidase (complex IV)wasassayed according to themethoddescribedby
Rustin et al. (1994), measured by following the decrease in absorbance
due to the oxidation of previously reduced cytochrome c at l=550 nm.
The activities of themitochondrial respiratory chain complexes were
calculated as nmol/min mg protein.
2.7. Creatine kinase activity
Creatine kinase (CK) activity was assessed in brain homogenates
pretreated with 0.625 mM lauryl maltoside. The reaction mixture
consisted of 60 mM Tris–HCl, pH 7.5, containing 7 mM of phosphocre-
atine, 9 mMofMgSO4 and approximately 0.4–1.2 μg of protein in a ﬁnal
volume of 100 μL. After 15 min of pre-incubation at 37 °C, the reaction
was started by the addition of 3.2 mmol of ADP plus 0.8 mmol of
reduced glutathione. The reaction was stopped after 10 min by the
addition of 1 μmol of p-hydroxymercuribenzoic acid. The creatine
formed was estimated according to the colorimetric method of Hughes
(1962). The coloring was developed through the addition of 100 μL of
2%α-naphtol and 100 μL of 0.05% diacetyl in a ﬁnal volume of 1 mL and
read spectrophotometrically after 20 min at 540 nm. Results were
expressed as mmol of creatine formed per min per mg protein.
2.8. Statistical analysis
Data were analyzed by two-way analysis of variance (ANOVA)
followed by Tukey test when p values were signiﬁcant (pb0.05). All
analyses were performed using the Statistical Package for the Social
Science (SPSS) version 17.0 software.
3. Results
3.1. Reversal model
As illustrated in Fig. 1, D-AMPH administration increased crossings
and rearings in saline-treated rats and this effect was reversed by TMXadministration. TMX alone did not alter behavioral parameters in this
protocol of treatment.
As shown in Fig. 2, in the reversal treatment TMX administration in
Sal-pretreated groups did not modify the complex viability (Fig. 2A, C
and D), except in hippocampus, where TMX decreased complex II
activity (Fig. 2B). The administration of D-AMPH resulted in a marked
inhibition of complexes I (Fig. 2A), II (Fig. 2B), III (Fig. 2C) and IV
(Fig. 2D) of mitochondrial respiratory chain in prefrontal cortex,
hippocampus, striatum and amygdala. In the hippocampus and
striatum the TMX administration partially reversed the decrease of
complex II activity induced by D-AMPH (Fig. 2B). On the other hand,
the inhibition of complex IV was totally reversed by this drug in all
brain regions analyzed (Fig. 2D). Conversely, TMX did not modiﬁed
the decreased activity of complex I (Fig. 2A) and III (Fig. 2C) in the
D-AMPH-treated group.
D-AMPHadministration signiﬁcantly inhibited CK activity in the rat's
hippocampus and striatum, but not in the amygdala and prefrontal
cortex (Fig. 3). The administration of TMX reversed D-AMPH-induced
inhibition of CK activity in hippocampus and striatum. Besides, in this
protocol of treatment CK activity was signiﬁcantly increased by the
treatment with TMX in D-AMPH-groups in the prefrontal cortex of the
rats.
3.2. Prevention model
Fig. 4 summarizes the results of locomotor activity in the
preventionmodel. Crossings and rearings were signiﬁcantly increased
by D-AMPH administration in saline-treated rats and TMX prevented
D-AMPH-related hyperactivity.
Results for mitochondrial respiratory chain complexes I, II, III and
IV activity are shown in Fig. 5. The treatment with Sal plus TMX
decreased the activity of complex II in amygdala and complex IV in
striatum. The administration of D-AMPH in the prevention protocol
also resulted in a marked inhibition of complexes I (Fig. 5A), II
(Fig. 5B), III (Fig. 5C) and IV (Fig. 5D) of mitochondrial respiratory
chain in prefrontal cortex, hippocampus, striatum and amygdala. The
inhibition of complexes I and III was totally prevented by TMX in all
brain regions analyzed (Fig. 5A and C, respectively). Furthermore,
TMX totally prevented D-AMPH-induced inhibition of complex II in
prefrontal cortex and amygdala, but no effect of TMX on the
mitochondrial alteration in the hippocampus and striatum was
observed (Fig. 5B). The administration of TMX signiﬁcantly decreased
the D-AMPH-induced complex IV inhibition in the prefrontal cortex,
hippocampus and amygdale. In addition, TMX administration de-
creased partially the inhibition of complex IV activity in striatum
(Fig. 5D).
In the treatment of prevention, TMX alone decreased CK activity in
amygdala, hippocampus and striatum, but not in the prefrontal cortex
Fig. 2. Numbers of crossings and rearings in prevention model. (n=12 for each group). Data were analyzed by two-way analysis of variances followed by Tukey test when p was
signiﬁcant. Values are expressed as mean±S.E.M. * pb0.05 difference of Sal+Sal group. # pb0.05 difference of D-AMPH+Sal group. Bars represent means; error bars represent
standard error of means.
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tration of D-AMPH resulted in a marked inhibition of CK activity in the
amygdala, hippocampus and striatum. The same was not observed in
the prefrontal cortex. In the hippocampus and amygdala, the
pretreatment with TMX potentiates the inhibition of CK activity
induced by AMPH. In addition, CK activity inhibition induced by
D-AMPH was not altered by the pretreatment with TMX in the striatum
of the rats. In the prefrontal cortex, the pretreatment with TMX
decreased CK activity in the D-AMPH-group.
4. Discussion
D-AMPH has profound effects on a wide range of physiological and
behavioral processes:motor activity, ingestive behavior, sleep, attention,
aggression, sexual behavior, learningandmemory, classical conditioning
and operant behavior (Seiden et al., 1993). Psychostimulant-induced
hyperactivity is the best established animal model of mania (Machado-Fig. 3. Mitochondrial respiratory chain complexes I, II, III and IV activity in prefrontal
cortex, hippocampus, striatum and amygdala in reversal model. (n=6 for each group).
Data were analyzed by two-way analysis of variances followed by Tukey test when
pwas signiﬁcant. Values are expressed as mean±S.E.M. * pb0.05 difference of Sal+Sal
group. # pb0.05 difference of D-AMPH+Sal group. Bars represent means; error bars
represent standard error of means.Vieira et al., 2004). The hyperactivity induced by D-AMPH has been
reported by several authors (Cappeliez andMoore, 1990; Einat et al.,
2007; Szabo et al., 2009; Young et al., 2010) and this effect is
mediated by an increased dopaminergic transmission in some brain
regions, moreover, antipsychotic drugs used to treat acute mania are
dopaminergic receptor antagonists (Meyer and Quenzer, 2005;
Kapczinski and Quevedo, 2009). So, the data of the present study are
in linewith previousﬁndingswhich showedconsistent hyperlocomotor
effects of D-AMPH in rats (Frey et al., 2006a,b,c,d; Mavrikaki et al., 2010;
Valvassori et al., 2010).
The reversion and prevention of D-AMPH-induced hyperlocomotion
were seen after treatment with TMX, whose main action is to inhibit
PKC, besides, the groups given TMX plus Sal did not differ from the
control groups (Sal+Sal), indicating that the effects of TMXcouldnotbe
attributed to sedation. This ﬁnding conﬁrms previous studies showing
that TMX reduced the hyperactivity induced by D-AMPH in the open-
ﬁeld test (Einat et al., 2007). Literature data also show that anotherFig. 4. Mitochondrial respiratory chain complexes I, II, III and IV activity in prefrontal
cortex, hippocampus, striatum and amygdala in prevention model. (n=6 for each
group). Data were analyzed by two-way analysis of variances followed by Tukey test
when p was signiﬁcant. Values are expressed as mean±S.E.M. * pb0.05 difference of
Sal+Sal group. # pb0.05 difference of D-AMPH+Sal group. Bars represent means;
error bars represent standard error of means.
Fig. 5. Creatine kinase (CK) activity in the amygdala, prefrontal cortex, hippocampus and striatum of rats following reversal treatment (n=5 for each group). Data were analyzed by
two-way analysis of variances followed by Tukey test when pwas signiﬁcant. Values are expressed as mean±S.E.M. * pb0.05 difference of Sal+Sal group. # pb0.05 difference of
D-AMPH+Sal group. Bars represent means; error bars represent standard error of means.
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accumbens, attenuates the motor response produced by D-AMPH, an
effect which was associated with the blocking of the dopamine release
(Browman et al., 1998). Additionally, Einat et al. (2007) showed that
the administration of D-AMPH increased phosphorylation of GAP-43
protein—implicated in neuronal differentiation, plasticity and neuro-
transmitter release—and that pretreatment with TMX eliminates the
effect of D-AMPH in this protein phosphorylation in parallel with
behavioral changes, reinforcing the importance of modulation of PKC in
the treatment of mania.
However, it is important to consider that TMX is also an estrogenic
receptor modulator (with estrogenic and antiestrogenic effects), which
could contribute to its behavioural effect. In this context, a study
evaluatedwhether the antimanic effect of TMX ismediated through the
PKC inhibitory and/or the antiestrogenic action(s) of the drug. TMX and
chelerythrine (a PKC inhibitor) completely blocked the hyperlocomo-
tion induced by D-AMPH. However, while the intermediate medroxy-
progesterone (an antiestrogenic drug) dose partially reduced theFig. 6. Creatine kinase (CK) activity in the amygdala, prefrontal cortex, hippocampus
and striatum of rats following prevention treatment (n=5 for each group). Data were
analyzed by two-way analysis of variances followed by Tukey test when p was
signiﬁcant. Values are expressed as mean±S.E.M. * pb0.05 difference of Sal+Sal
group. # pb0.05 difference of D-AMPH+Sal group. Bars represent means; error bars
represent standard error of means.D-AMPH-induced hyperlocomotion, lower and high doses produced
no effect (Sabioni et al., 2008), indicating a major role for PKC
inhibition in the antimanic-like effect of TMX.
Our results also showed that D-AMPH administration resulted in
an inhibition of complexes I, II, III and IV of mitochondrial respiratory
chain in prefrontal cortex, hippocampus, striatum and amygdala,
conﬁrming previous studies that demonstrated a dysfunction in
mitochondrial function during mania (Andreazza et al., 2010).
Several evidences have shown that the activation of PKC enhances
the release of dopamine, a neurotransmitter implicated in the manic
syndrome (Robinson, 1991; Cowell et al., 2000;) and that PKC
inhibition reduces dopamine release induced by D-AMPH (Giambalvo,
1992; Kantor and Gnegy, 1998). In this context, Przedborski et al.
(1993) showed that the administration of levodopa (L-DOPA), the
precursor of dopamine, was able to inhibit the activity of complex I in
rat brains. This group also demonstrated that the incubation of
mitochondria with dopamine and L-DOPA inhibited the activity of
complex I in a time-dependent way, strengthening the link between
dopaminergic hyperactivity and mitochondrial damage. Moreover,
high levels of DA are related to increased cerebral oxidative stress and
damage to mitochondrial function due to metabolism of oxidation of
this monoamine (Kapczinski and Quevedo, 2009). In addition, it is
important to emphasize that the increased activity of PKC induced by
the administration of D-AMPH is related to an increased Ca2 + inﬂux
(Yang and Kazanietz, 2003). A large movement of positive charges of
Ca2 + into mitochondria increases the permeability of the mitochon-
drial membrane, decreasing its potential and exerting a depolarising
effect (Quiroz et al., 2008). These aspects are linked with the
interruption of oxidative phosphorylation and production of ATP,
with consequent release of cytochrome c and cell death by apoptosis
(Rasola et al., 2010). Together with our results, these studies suggest
that inhibition of PKC, with consequent decrease in dopamine release
is able to protect mitochondrial respiratory chain complexes viability
against damage induced by D-AMPH.
Here, we found that the inhibition of themitochondrial respiratory
chain complexes was prevented by TMX, however it varies depending
Table 1
Summary of tamoxifen effects on D-AMPH-induced behavioral and biochemical alteration in an animal model of mania-reversal treatment. ↓=decrease; Rev=Reversion of D-AMPH
effects; PC=Prefrontal cortex; HIP=Hippocampo; STR=Striatum; AMY=Amygdala.
Locomotor activity Complex I activity Complex II activity Complex III activity Complex IV activity CK activity Brain structures
D-AMPH ↑ ↓ ↓ ↓ ↓ – PC
↓ ↓ ↓ ↓ ↓ HIP
↓ ↓ ↓ ↓ ↓ STR
↓ ↓ ↓ ↓ – AMY
TMX Rev – – – – – PC
– Rev – – Rev HIP
– Rev – – Rev STR
– – – – – AMY
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evaluated, whichmay have occurred due to the longer treatment with
SB in the reversal model when compared to the prevention protocol.
Furthermore, regions of the central nervous system can respond
distinctly (Sullivan et al., 2005), and the activity of mitochondrial
respiratory chain complexes was analyzed in different brain regions,
which in part represent different cell types, indicating heterogeneity
in terms of physiological and metabolic characteristics (Lai et al.,
1977; Sims, 1991; Sonnewald et al., 1998). Another interesting fact is
that the treatment with Lithium and valproate—both PKC inhibitors—
reverses the inhibition of mitochondrial respiratory chain complexes
induced by D-AMPH (Valvassori et al., 2000), results that are in
agreement with those obtained in this study.
We also demonstrated that D-AMPH administration signiﬁcantly
inhibited CK activity in rat hippocampus and striatum. These results
are consistent with a previous study of our research group (Streck
et al., 2008). In a postmortem study MacDonald et al. (2006) also
demonstrated that levels of CK mRNA are decreased in BD patients,
especially in the hippocampus. Together these studies suggest that the
decrease in CK may have a role in BD.
Herewe showed that TMX reverses the D-AMPH-induced CK activity
inhibition. Conversely, the administration of lithium and valproate—
mood stabilizers that inhibit PKC—in D-AMPH-treated animals did not
reverse the inhibition of the CK activity (Streck et al., 2008). This
discrepancymaybedue to the fact that lithiumandvalproate haveother
mechanisms of action in addition to PKC inhibition, suggesting that
speciﬁc inhibition of PKC by TMXmay be a relationwith CKmodulation.
Additionally, it is important to emphasize that TMX acts on estrogen
receptor. Recently, studies have found that estrogen receptor agonists
and antagonists stimulate energy metabolism, including CK activity
(Somjen et al., 2008, 2010, 2011). Together with our ﬁndings, these
studies suggest that the modulation of CK by TMX can be via estrogen
action.
On the other hand, in the prevention model, TMX decreased CK
activity, both alone and co-administered with D-AMPH. According to
our results, in a study that examined the effects of TMX in rats
subjected to myocardial ischemia-reperfusion injury it was observed
that the blood levels of CK were reduced after treatment with this
drug (Ek et al., 2008). Furthermore, CK activity in homogenate of
hearts was inactivated by TMX about 20% at 10 mM of this drugTable 2
Summary of tamoxifen effects on D-AMPH-induced behavioral and biochemical alteration in an
effects. PC=Prefrontal cortex; HIP=Hippocampo; STR=Striatum; AMY=Amygdala.
Locomotor activity Complex I activity Complex II activity




TMX Prev Prev Prev
Prev –
Prev –
Prev Prev(Miura et al., 2002). This discrepancy may be explained due to the
longer treatment with TMX in the prevention model compared to the
reversal model, whichmay be causing adaptations andmodulations in
CK activity depending on the time of treatment with this drug.
The main limitation of this study is that TMX mechanism of action
also involves estrogen receptor modulation, as previously mentioned.
However, studies have indicated that this effects may contribute to its
antimanic-like action (Sabioni et al., 2008), moreover, it was demon-
strated that addition of medroxyprogesterone in drug treatment
improves mood in female patients with refractory mood disorder
(Chouinard et al., 1987), encouraging the use of antiestrogenic drugs as
an another approach in the search for new mood stabilizing drugs.
5. Conclusion
In conclusion, the present study suggests that the mechanism of
TMX action involves changes in the mitochondrial respiratory chain
complexes and creatine kinase activities in parallel with behavioral
changes, thus reinforcing the need for the study of inhibitors of PKC as
a possible target for new medications to BD (Tables 1 and 2).
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